Systemic Lupus Erythematosus – our new study reveals trends, R&D progress, and predicted revenues
Where is the SLE market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.
Discover How to Stay Ahead
Our 152-page report provides 114 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing SLE market. See how to exploit the opportunities.
Forecasts to 2027 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are forecasts for 7 Products, 3 Molecule Types and 4 Pharmacological Classes
Systemic Lupus Erythematosus Market Forecasts to 2027, By Product
• Atacicept
• Benlysta
• Anifrolumab
• Lulizumab
• Bisibimod
• CellCept
• Prograf
Systemic Lupus Erythematosus Market Forecasts to 2027, By Molecule Type
• Small Molecules
• Monoclonal Antibodies
• Recombinant Proteins
Systemic Lupus Erythematosus Market Forecasts to 2027, By Pharmacological Class
• B-Cell Targeting Therapies
• Interferon Receptor Antagonists
• CD Antagonist Therapies
• Other Therapies for SLE
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 2 regional and 9 leading national markets:
• Regional Markets:
• LATAM (including Brazil)
• Asia Pacific
• National Markets:
• The US
• Canada
• Germany
• France
• The UK
• Italy
• Spain
• Japan
• China
The report also includes profiles and forecasts for some of the leading companies in the Systemic Lupus Erythematosus market, with a focus on the SLE segment of these companies’ operations.
There will be growth in both established and in developing countries. Our analyses show that the developing markets, China in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market.
Leading companies and the potential for market growth
Overall world revenue for SLE will surpass $570m in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing prevalence of autoimmune disease, and increasing ageing population will increase sales to 2027.
Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the SLE Market report helps you
In summary, our 152-page report provides you with the following knowledge:
• Revenue forecasts to 2027 for the world Systemic Lupus Erythematosus market and 3 different segmentations, with forecasts for 7 Products, 3 Molecule Types and 4 Pharmacological Classes – discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2027 for 2 regional markets and 9 of the leading national markets – LATAM (Including Brazil), APAC, US, Canada, Germany, UK, France, Italy, Spain, Japan, China,
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the Systemic Lupus Erythematosus market and leading companies. You will find data, trends and predictions.
Get our report today The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027: Revenue Prospects by Product, Molecule Type (Small Molecules, mAbs, Recombinant Proteins), Pharmacological Class (B-Cell Targeting, Interferon Receptor Antagonists, CD Antagonists, Other) and Geography. Avoid missing out – get our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Systemic Lupus Erythematosus (SLE) Market Definition
1.2 Methodology
1.2.1 Primary Research
1.2.2 Secondary Research
1.2.3 Market Evaluation & Forecasting Methodology
1.3 Systemic Lupus Erythematosus (SLE) Report Structure
1.4 Why You Should Read This Report
1.5 How this Report Delivers
1.6 Key Questions Answered by This Analytical Report Include:
1.7 Who is This Report For?
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Systemic Lupus Erythematosus
2.1 Aetiology
2.2 Pathophysiology
2.3 Constitutional
2.4 Prognosis
2.5 Symptoms
2.6 Diagnosis
2.7 Assessing the Health Status of SLE patients
2.8 Current Treatment Options
2.9 Unmet Needs
3. Epidemiology
3.1 Prevalence
3.2 Incidence Rates (New Cases/Year)
3.3 Mortality
3.4 Hospitalizations
3.5 Ambulatory Care
3.6 Costs
3.7 Impact on Health-Related Quality of Life (HRQOL)
4. Systemic Lupus Erythematosus Market Forecast 2017-2027
4.1 Total population in US, EU, Japan and China
4.2 Systemic Lupus Erythematosus Prevalence Rate in US, EU, Japan and China
4.3 Diagnosed Systemic Lupus Erythematosus Population in US, EU, Japan and China
4.4 Systemic Lupus Erythematosus Drug Treated Patients in US, EU, Japan and China
4.5 Pricing Trends of the Market
4.6 Atacicept Sales Forecast 2017-2027
4.7 Benlysta Sales Forecast 2017-2027
4.8 Anifrolumab Sales Forecast 2017-2027
4.9 Lulizumab Sales Forecast 2017-2027
4.10 Bisibimod Sales Forecast 2017-2027
4.11 CellCept Sales Forecast 2017-2027
4.12 Prograf Sales Forecast 2017-2027
4.13 All Key SLE Therapies Sales
5. Product Profiles
5.1 Anifrolumab (AstraZeneca)
5.2 Atacicept (Merck)
5.3 Baricitinib (Eli Lilly)
5.4 Benlysta (GlaxoSmithKline)
5.5 Blisibimod (Anthera)
5.6 Lupuzor (ImmuPharma)
6. SLE Market Forecast By Molecule Type 2017-2027
6.1 Small Molecules Sales Forecast 2017-2027
6.2 Monoclonal Antibodies Sales Forecast 2017-2027
6.3 Recombinant Proteins Sales Forecast 2017-2027
6.4 Comparative Sales Analysis
6.5 Market Share – By Molecule Type
7. SLE Market Forecast by Pharmacological Class 2017-2027
7.1 B-Cell Targeting Therapies Sales Forecast 2017-2027
7.2 Interferon Receptor Antagonist Sales Forecast 2017-2027
7.3 CD Antagonist Therapies Sales Forecast 2017-2027
7.4 Other Therapies for SLE
7.5 Market Share – By Pharmacological Class Sales
7.6 Market Share – By Pharmacological Class Sales
7.7 Comparative analysis – Sales by Pharmacological Class Sales
8. Leading National Markets in the Systemic Lupus Erythematosus Market
8.1 US SLE Sales Forecast 2017-2027
8.2 Japan SLE Sales Forecast 2017-2027
8.3 China SLE Sales Forecast 2017-2027
8.4 LATAM (Including Brazil) SLE Sales Forecast 2017-2027
8.5 UK SLE Sales Forecast 2017-2027
8.6 France SLE Sales Forecast 2017-2027
8.7 Germany SLE Sales Forecast 2017-2027
8.8 Italy SLE Sales Forecast 2017-2027
8.9 Spain SLE Sales Forecast 2017-2027
8.10 Canada SLE Sales Forecast 2017-2027
8.11 APAC SLE Sales Forecast 2017-2027
8.12 Comparative analysis – EU Sales
8.13 Market Share – By EU Countries Sales
8.14 Market Share – By EU Countries Sales
8.15 Comparative analysis – US and EU Sales
8.16 Comparative analysis – China and Japan Sales
8.17 Comparative analysis – APAC and LATAM Sales
8.18 Comparative analysis – Key Market Sales
9. Product Launch timelines
9.1 Timeline of USA Launches
9.2 Timeline of EU Launches
9.3 Timeline of Japan Launches
10. Company Profiles
10.1 Anthera Company Profile
10.1.1 Anthera Company Overview
10.1.2 Anthera Projects Overview
10.1.3 Anthera Recent Deals
10.2 GSK Company Profile
10.2.1 GSK Company Overview
10.2.2 GSK Projects Overview
10.2.3 GSK Recent Deals
10.3 ImmuPharma Company Profile
10.3.1 ImmuPharma Company Overview
10.3.2 ImmuPharma Projects Overview
10.3.3 ImmuPharma Recent Deals
10.4 Merck Company Profile
10.4.1 Merck KGaA Company Overview
10.4.2 Merck Projects Overview
10.4.3 Merck Recent Deals
10.5 AstraZeneca Company Profile
10.5.1 AstraZeneca Company Overview
10.5.2 AstraZeneca Projects Overview
10.5.3 AstraZeneca Recent Deals
10.6 Eli Lilly Company Profile
10.6.1 Eli Lilly Company Overview
10.6.2 Eli Lilly Projects Overview
10.6.3 Eli Lilly Recent Deals
10.7 Other SLE companies
11. Qualitative Analysis of the Systemic Lupus Erythematosus Market
11.1 Strengths of the Systemic Lupus Erythematosus Market
11.2 Weakness of the Systemic Lupus Erythematosus Market
11.3 Opportunities for the Systemic Lupus Erythematosus Market
11.4 Threats for the Systemic Lupus Erythematosus Market
11.5 Political Factors Influencing the Systemic Lupus Erythematosus Market
11.6 Economical Factors Influencing the Systemic Lupus Erythematosus Market
11.7 Social Factors Influencing the Systemic Lupus Erythematosus Market
11.8 Technological Factors influencing the Systemic Lupus Erythematosus market
12. Key Findings and Report Conclusion
12.1 Cost of Therapies in Systemic Lupus Erythematosus
12.2 Geographical Trends of Systemic Lupus Erythematosus Market
12.3 Future of the Systemic Lupus Erythematosus Market
13. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Figures
Figure 4.1 Atacicept Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 4.2 Benlysta Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 4.3 Anifrolumab Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 4.4 Lulizumab Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 4.5 Bisibimod Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 4.6 CellCept Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 4.7 Prograf Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 4.8 All Key SLE Therapies Sales 2017-2027
Figure 6.1 Small Molecules Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 6.2 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 6.3 Recombinant Proteins Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 6.4 Comparative analysis Sales 2017-2027
Figure 6.5 Market Share – By Molecule Type Sales 2022
Figure 6.6 Market Share – By Molecule Type Sales 2027
Figure 7.1 B- Cell Targeting Therapies Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 7.2 Interferon Receptor Antagonist Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 7.3 CD Antagonist Therapies Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 7.4 Other Therapies in SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 7.5 Market Share – By Pharmacological Class Sales 2022
Figure 7.6 Market Share – By Pharmacological Class Sales 2027
Figure 7.7 Comparative analysis – Sales by Pharmacological Class Sales 2017-2027
Figure 8.1 US SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.2 Japan SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.3 China SLE Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.4 LATAM (Including Brazil) SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.5 UK SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.6 France SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.7 Germany SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.8 Italy SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.9 Spain SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.10 Canada SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.11 APAC SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.12 Comparative analysis – EU-5 Sales 2017-2027
Figure 8.13 Market Share – By EU-5 Countries Sales 2022
Figure 8.14 Market Share – By EU-5 Countries Sales 2027
Figure 8.15 Comparative analysis – US and EU-5 Sales 2017-2027
Figure 8.16 Comparative analysis – China and Japan Sales 2017-2027
Figure 8.17 Comparative analysis – APAC and LATAM Sales 2017-2027
Figure 8.18 Comparative analysis – Key Market Sales 2017-2027
Figure 10.1 Anthera project overview by development stage
Figure 10.2 Anthera project overview by Therapeutic area
Figure 10.3 GSK project overview by development stage
Figure 10.4 GSK project overview by Therapeutic area
Figure 10.5 ImmuPharma project overview by development stage
Figure 10.6 Immupharma project overview by Therapeutic area
Figure 10.7 Merck project overview by development stage
Figure 10.8 Merck project overview by Therapeutic area
Figure 10.9 AstraZeneca project overview by development stage
Figure 10.10 AstraZeneca project overview by Therapeutic area
Figure 10.11 Eli Lilly project overview by development stage
Figure 10.12 Eli Lilly project overview by Therapeutic area
List of Tables
Table 2.1 Diagnostic Tests for Systemic Lupus Erythematosus
Table 2.1 Diagnostic Tests for Systemic Lupus Erythematosus (continued)
Table 2.1 Diagnostic Tests for Systemic Lupus Erythematosus (continued)
Table 4.1 Total Country Population Forecast (in millions)
Table 4.2 Overall Systemic Lupus Erythematosus Prevalence Rate (per 100k population)
Table 4.3 Diagnosed Systemic Lupus Erythematosus Population (‘000)
Table 4.4 Systemic Lupus Erythematosus Drug Treated Patients
Table 4.5 Atacicept Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 4.7 Benlysta Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 4.8 Anifrolumab Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 4.9 Lulizumab Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 4.10 Bisibimod Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 4.11 CellCept Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 4.12 Prograf Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 4.13 All Key SLE Therapies Market Forecast: Revenues ($m) 2017-2027
Table 6.1 Small Molecules Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 6.2 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 6.3 Recombinant Proteins Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 6.4 Comparative analysis Market Forecast: Revenues ($m) 2017-2027
Table 6.5 Market Share – By Molecule Type Revenues ($m) 2022
Table 6.6 Market Share – By Molecule Type Revenues ($m) 2027
Table 7.1 B- Cell Targeting Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 7.2 Interferon Receptor Antagonist Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 7.3. CD Antagonist Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 7.4 Other Therapies in SLE Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 7.5 Market Share – By Pharmacological Class Revenues ($m) 2022
Table 7.6 Market Share – By Pharmacological Class Revenues ($m) 2027
Table 7.7 Comparative analysis – Sales by Pharmacological Class Revenues ($m) 2017-2027
Table 8.1 US SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.2 Japan SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.3 China SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.4 LATAM (Including Brazil) SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.5 UK SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.6 France SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.7 Germany SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.8 Italy SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.9 Spain SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.10 Canada SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.11 APAC SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.12 Comparative analysis – EU-5 Revenues ($m) 2017-2027
Table 8.13 Market Share – By EU-5 Countries Revenues ($m) 2022
Table 8.15 Comparative analysis – US and EU-5 Revenues ($m) 2017-2027
Table 8.16 Comparative analysis – China and Japan Revenues ($m) 2017-2027
Table 8.17 Comparative analysis – APAC and LATAM Revenues ($m) 2017-2027
Table 8.18 Comparative analysis – Key Market Revenues ($m)2017-2027
Table 9.1 Timeline of USA Launches
Table 9.2 Timeline of EU Launches
Table 9.3 Timeline of Japan Launches
Table 10.1 Anthera Company Overview
Table 10.2 Anthera Key licensing deals
Table 10.3 GSK Company Overview
Table 10.4 GSK Key Licensing deals
Table 10.5 ImmuPharma Company Overview
Table 10.6 ImmuPharma Licensing deal
Table 10.7 Merck Company Overview
Table 10.8 Merck Key Licensing deals
Table 10.9 AstraZeneca Company Overview
Table 10.10 AstraZeneca Key licensing deals
Table 10.11 Eli Lilly Company Overview
Table 10.12 Eli Lilly Key licensing deals
Table 10.13 Other companies involved in the SLE market
Table 10.13 Other companies involved in the SLE market (continued)
Table 11.1 Strengths and Weakness of the Systemic Lupus Erythematosus Market
Table 11.2 Opportunities and Threats for the Systemic Lupus Erythematosus Market
Table 11.3 Political, Economical, Social and technological Factors influencing Systemic Lupus Erythematosus Market
3SBio
AbbVie
Ablynx
Actelion
Active Biotech
Alkermes
Allergan
AMEGA Biotech
Amgen
AstraZeneca
Aurinia Pharmaceuticals
Beijing SL Pharmaceutical
Biogen
BioSense Global
Biotest
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chong Kun Dang
CipherPharmaceuticals
CSL
Eli Lilly
GSK
Helion Biotech
Idera Pharmaceuticals
ILTOO Pharma
Immungenetics
Immunomedics
ImmuPharma
Incyte
Innovent Biologics
Intrexon
Invion
Ionis Pharmaceuticals
Japan Tobacco
Johnson & Johnson
Kadmon
Ligand Pharmaceuticals
MacroGenics
Medsenic
Merck
Mitsubishi Tanabe Pharma
Nano Terra
Nektar Therapeutics
Neovacs
Omeros
Ono Pharmaceutical
PDL BioPharma
Pfizer
Resolve Therapeutics
Roche
Sanofi
Seattle Genetics
Shenzhen Beike Biotechnology
Shire
Takeda
Teva
TheraMAB
UCB
Weizmann Institute of Science
Xencor
XTL Biopharmaceuticals
List of Organizations
Aarhus University
Charité Universitätsmedizin Berlin
Development Center for Biotechnology
Food and Drug Administration (FDA)
Ministry of Health, Labor, and Welfare (MHLW)
National Health Service (UK)
National Institutes of Health (NIH)
University of Leicester
University of Miami
University of Washington
World Health Organization (WHO)
